CTD-O 6.25/20 Tablet
By CTD-O
Rx
10 Tablet in a Strip

Composition
Olmesartan Medoxomil(20mg) + Chlorthalidone(6.25mg)

Manufacturer - Ipca Laboratories Ltd
142 AB, Kandivli Industrial Estate, Kandivli (West), Mumbai - 400 067, Maharashtra

Expires on or after
October, 2026

liver
When using CTD-O 6.25/20 Tablet, it's important to be cautious if you have a liver disease. You may need a dose adjustment, so always consult your doctor before taking this medication. It's advisable not to use CTD-O 6.25/20 Tablet if you have severe liver disease. Remember to seek medical advice to ensure the safe use of this medication.

kidney
CTD-O 6.25/20 Tablet should be used carefully by patients with severe kidney disease. Dosage adjustment might be necessary, so consulting your doctor is advised. Avoid using CTD-O 6.25/20 Tablet in these cases.

alcohol
CTD-O 6.25/20 Tablet can increase drowsiness when taken with alcohol.

driving
CTD-O 6.25/20 Tablet may cause reduced alertness, blurred vision, drowsiness, and dizziness. Avoid driving if experiencing these effects.

pregnancy
CTD-O 6.25/20 Tablet is not safe to use during pregnancy due to potential risks to the developing baby. However, in life-threatening situations, a doctor may prescribe it if benefits outweigh risks. Always consult your doctor.

breastfeeding
CTD-O 6.25/20 Tablet should be used with caution during breastfeeding, as it is considered unsafe. Limited human data indicates that the drug may pass into breastmilk and potentially harm the baby.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | CARDIAC |
Action Class | - |
₹154.25
Inclusive of all taxes
Content verified by

Dr. Abdullah Khan
MBBS - General Medicine
Last update on 01-Oct-2024